Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

299 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Survival benefit of HER2-targeted or androgen deprivation therapy in salivary duct carcinoma.
Kawakita D, Nagao T, Takahashi H, Kano S, Honma Y, Hirai H, Saigusa N, Akazawa K, Tani K, Ojiri H, Tsukahara K, Ozawa H, Okami K, Kondo T, Togashi T, Fushimi C, Shimura T, Shimizu A, Okamoto I, Okada T, Imanishi Y, Watanabe Y, Otsuka K, Sakai A, Ebisumoto K, Sato Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Ando M, Matsuki T, Nakaguro M, Sato Y, Urano M, Utsumi Y, Kohsaka S, Saotome T, Tada Y. Kawakita D, et al. Among authors: urano m. Ther Adv Med Oncol. 2022 Sep 6;14:17588359221119538. doi: 10.1177/17588359221119538. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 36090801 Free PMC article.
The clinicopathological significance of the adipophilin and fatty acid synthase expression in salivary duct carcinoma.
Hirai H, Tada Y, Nakaguro M, Kawakita D, Sato Y, Shimura T, Tsukahara K, Kano S, Ozawa H, Okami K, Sato Y, Fushimi C, Shimizu A, Okamoto I, Takase S, Okada T, Sato H, Imanishi Y, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Saigusa N, Takahashi H, Ando M, Urano M, Hanazawa T, Nagao T. Hirai H, et al. Among authors: urano m. Virchows Arch. 2020 Aug;477(2):291-299. doi: 10.1007/s00428-020-02777-w. Epub 2020 Feb 26. Virchows Arch. 2020. PMID: 32103349 Free PMC article.
The Role of the EZH2 and H3K27me3 Expression as a Predictor of Clinical Outcomes in Salivary Duct Carcinoma Patients: A Large-Series Study With Emphasis on the Relevance to the Combined Androgen Blockade and HER2-Targeted Therapy.
Saigusa N, Hirai H, Tada Y, Kawakita D, Nakaguro M, Tsukahara K, Kano S, Ozawa H, Kondo T, Okami K, Togashi T, Sato Y, Urano M, Kajiwara M, Shimura T, Fushimi C, Shimizu A, Okamoto I, Okada T, Suzuki T, Imanishi Y, Watanabe Y, Sakai A, Ebisumoto K, Sato Y, Honma Y, Yamazaki K, Ueki Y, Hanazawa T, Saito Y, Takahashi H, Ando M, Kohsaka S, Matsuki T, Nagao T. Saigusa N, et al. Among authors: urano m. Front Oncol. 2022 Feb 3;11:779882. doi: 10.3389/fonc.2021.779882. eCollection 2021. Front Oncol. 2022. PMID: 35186711 Free PMC article.
The high expression of FOXA1 is correlated with a favourable prognosis in salivary duct carcinomas: a study of 142 cases.
Urano M, Hirai H, Tada Y, Kawakita D, Shimura T, Tsukahara K, Kano S, Ozawa H, Okami K, Sato Y, Fushimi C, Shimizu A, Takase S, Okada T, Sato H, Imanishi Y, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Sato Y, Saigusa N, Nakaguro M, Hanazawa T, Nagao T. Urano M, et al. Histopathology. 2018 Dec;73(6):943-952. doi: 10.1111/his.13706. Epub 2018 Sep 25. Histopathology. 2018. PMID: 29993139
Prognostic Implication of Histopathologic Indicators in Salivary Duct Carcinoma: Proposal of a Novel Histologic Risk Stratification Model.
Nakaguro M, Sato Y, Tada Y, Kawakita D, Hirai H, Urano M, Shimura T, Tsukahara K, Kano S, Ozawa H, Okami K, Sato Y, Fushimi C, Shimizu A, Takase S, Okada T, Sato H, Imanishi Y, Otsuka K, Watanabe Y, Sakai A, Ebisumoto K, Togashi T, Ueki Y, Ota H, Saigusa N, Takahashi H, Ando M, Hanazawa T, Nagao T. Nakaguro M, et al. Among authors: urano m. Am J Surg Pathol. 2020 Apr;44(4):526-535. doi: 10.1097/PAS.0000000000001413. Am J Surg Pathol. 2020. PMID: 31764219
The impact of clinicopathological factors on clinical outcomes in patients with salivary gland adenoid cystic carcinoma: a multi-institutional analysis in Japan.
Kawakita D, Murase T, Ueda K, Kano S, Tada Y, Tsukahara K, Okami K, Onitsuka T, Fujimoto Y, Matoba T, Sakurai K, Nagao T, Hanai N, Kawata R, Hato N, Nibu KI, Urano M, Taguchi KI, Nakaguro M, Kusafuka K, Yamamoto H, Nagao T, Inagaki H. Kawakita D, et al. Among authors: urano m. Int J Clin Oncol. 2020 Oct;25(10):1774-1785. doi: 10.1007/s10147-020-01731-9. Epub 2020 Jul 1. Int J Clin Oncol. 2020. PMID: 32613404
Central pathology review of salivary gland adenoid cystic carcinoma.
Ueda K, Murase T, Nagao T, Kusafuka K, Urano M, Yamamoto H, Nakaguro M, Taguchi KI, Masaki A, Hirai H, Kawakita D, Tsukahara K, Hato N, Nagao T, Fujimoto Y, Sakurai K, Hanai N, Kano S, Onitsuka T, Okami K, Nibu KI, Tada Y, Kawata R, Inagaki H. Ueda K, et al. Among authors: urano m. Head Neck. 2020 Aug;42(8):1721-1727. doi: 10.1002/hed.26081. Epub 2020 Jan 23. Head Neck. 2020. PMID: 31970840
Prognostic impact of CRTC1/3-MAML2 fusions in salivary gland mucoepidermoid carcinoma: A multiinstitutional retrospective study.
Okumura Y, Nakano S, Murase T, Ueda K, Kawakita D, Nagao T, Kusafuka K, Urano M, Yamamoto H, Kano S, Tsukahara K, Okami K, Nagao T, Hanai N, Iwai H, Kawata R, Tada Y, Nibu KI, Inagaki H. Okumura Y, et al. Among authors: urano m. Cancer Sci. 2020 Nov;111(11):4195-4204. doi: 10.1111/cas.14632. Epub 2020 Sep 14. Cancer Sci. 2020. PMID: 32860299 Free PMC article.
Pathological evaluation of tumor grade for salivary adenoid cystic carcinoma: A proposal of an objective grading system.
Morita N, Murase T, Ueda K, Nagao T, Kusafuka K, Nakaguro M, Urano M, Taguchi KI, Yamamoto H, Kano S, Tada Y, Tsukahara K, Okami K, Onitsuka T, Fujimoto Y, Kawakita D, Sakurai K, Nagao T, Hanai N, Kawata R, Hato N, Otsuki N, Nibu KI, Inagaki H. Morita N, et al. Among authors: urano m. Cancer Sci. 2021 Mar;112(3):1184-1195. doi: 10.1111/cas.14790. Epub 2021 Feb 2. Cancer Sci. 2021. PMID: 33377247 Free PMC article.
Salivary mucoepidermoid carcinoma: histological variants, grading systems, CRTC1/3-MAML2 fusions, and clinicopathological features.
Nakano S, Okumura Y, Murase T, Nagao T, Kusafuka K, Urano M, Yamamoto H, Kano S, Tsukahara K, Okami K, Kawakita D, Nagao T, Hanai N, Iwai H, Kawata R, Tada Y, Nibu KI, Inagaki H. Nakano S, et al. Among authors: urano m. Histopathology. 2022 Mar;80(4):729-735. doi: 10.1111/his.14586. Epub 2021 Dec 14. Histopathology. 2022. PMID: 34657306
299 results